• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aytu BioPharma Inc.

    8/15/22 10:01:55 AM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AYTU alert in real time by email
    SC 13G 1 tm2223289d2_sc13g.htm SC 13G

     

    CUSIP No:      054754874

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED 

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Aytu BioPharma, Inc.
    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share 

    (Title of Class of Securities)

     

    054754874
    (CUSIP Number)

     

    August 10, 2022 

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

    xRule 13d-1(c)

    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No:      054754874

     

    (1)  NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)     ¨
        (b)     ¨
     
    (3)  SEC USE ONLY
     
    (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0
     
    BENEFICIALLY (6) SHARED VOTING POWER **
         
    OWNED BY 3,400,000
         
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING 0
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      3,400,000
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      3,400,000
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
         ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      5.6%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No:      054754874

     

    (1)  NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)     ¨
        (b)     ¨
     
    (3)  SEC USE ONLY
     
    (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0
     
    BENEFICIALLY (6) SHARED VOTING POWER **
         
    OWNED BY 3,400,000
         
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING 0
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      3,400,000
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      3,400,000
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
         ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      5.6%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No:      054754874

     

    Item 1.

     

    (a)Name of Issuer

     

    Aytu BioPharma, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    373 Inverness Parkway, Suite 206, Englewood, CO 80112

     

    Item 2(a).     Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).     Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House 

    South Church Street 

    George Town 

    Grand Cayman 

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c).     Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)      Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)      CUSIP Number

     

    054754874

     

     

     

    CUSIP No:      054754874

     

    Item 3.     If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.          Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The Company’s Prospectus Supplement (to Prospectus dated October 7, 2021, Registration No. 333-259862), filed on August 10, 2022, indicates there were 60,682,727 Shares outstanding (excluding Shares underlying warrants and pre-funded warrants issued at the same time) as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.          Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

     

     

    CUSIP No:      054754874

     

    Item 6.          Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.          Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.          Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.          Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.        Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No:      054754874

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: August 15, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
           
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto   Name:     Brian Sopinsky
      Title:         Secretary
           
    By: /s/ Brian Sopinsky      
    Name:    Brian Sopinsky      
    Title:         Secretary      

     

     

     

    CUSIP No:      054754874

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

     

    CUSIP No:      054754874

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

      CVI Investments, Inc.
         
      By: /s/ William Walmsley
        William Walmsley, Director

     

     

     

    CUSIP No:      054754874

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Aytu BioPharma, Inc., $0.0001 par value per share, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of August 15, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
           
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney   Name:    Brian Sopinsky
        Title:      Secretary
    By: /s/ Brian Sopinsky      
    Name:    Brian Sopinsky      
    Title:      Secretary      

     

     

    Get the next $AYTU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYTU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AYTU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

      DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.The fireside chat will take place at 10:00 a.m. Eastern Time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/aytu. A replay of the fireside chat will also be available through same links.1

      1/6/25 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Disclosure Notification

      DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL., NO. 2022-0807-MTZ (THE "ACTION").TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. ("AYTU" OR THE "COMPANY") (NASDAQ:AYTU) AS OF OCTOBER 9, 2024 (THE "RECORD DATE") ("CURRENT AYTU SHAREHOLDERS").YOU ARE HEREBY NOTIFIED that the Settling Parties to the Action have reached a settlement ("Settlement") to resolve the issues raised in the Action against Defendants

      12/3/24 11:45:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

      DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "During fiscal 2024, we continued to successfully reposition

      11/22/24 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Aytu BioPharma Inc.

      DEFA14A - AYTU BIOPHARMA, INC (0001385818) (Filer)

      3/28/25 4:03:19 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aytu BioPharma Inc.

      DEF 14A - AYTU BIOPHARMA, INC (0001385818) (Filer)

      3/28/25 4:02:19 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aytu BioPharma Inc.

      10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)

      2/12/25 4:12:32 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Pyszczymuka Greg converted options into 209 shares, increasing direct ownership by 0.89% to 23,602 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/31/25 4:34:24 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Selhorn Ryan J converted options into 105 shares, increasing direct ownership by 0.66% to 16,000 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 7:22:47 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Aytu BioPharma with a new price target

      Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00

      3/30/21 6:27:35 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Financials

    Live finance-specific insights

    See more
    • Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

      Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann

      11/13/24 4:05:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

      DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-

      11/6/24 5:20:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

      Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel ther

      9/26/24 4:15:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Leadership Updates

    Live Leadership Updates

    See more
    • Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

      Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to

      11/30/23 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

      ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we

      1/4/22 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

      - Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali

      5/17/21 4:01:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      11/13/24 5:36:50 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aytu BioPharma Inc.

      SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      6/18/24 4:30:29 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aytu BioPharma Inc. (Amendment)

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      2/13/24 4:25:46 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care